Data from Across Incyte's Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual

Related Keywords

Germany ,Turkey ,United Kingdom ,China ,Norway ,Delaware ,United States ,Canada ,Switzerland ,Chicago ,Illinois ,Israel ,Italy ,Russia ,American ,Tafasitamab Monjuvi ,Gewinn Nur ,Catalina Loveman ,Ponatinib Iclusig ,Steven Stein ,Greg Shertzer ,European Hematology Association ,Lymphoma Biology Translational Research ,Xencor Inc ,Macrogenics Inc ,Marrow Transplant Research ,European Union ,Millennium Pharmaceuticals Inc ,Incyte Corporation ,American Society Of Clinical Oncology ,Takeda Pharmaceuticals International ,Takeda Pharmaceutical Company ,International Blood ,Exchange Commission ,Drug Administration ,Clinical Oncology ,Annual Meeting ,Hybrid Congress ,Chief Medical Officer ,Activin Receptor Like Kinase ,Hematologic Malignancies Leukemia ,Myelodysplastic Syndromes ,Open Label Study ,Add On Therapy ,Suboptimal Response ,Combination Therapy ,Advanced Solid Tumors ,Cytokine Release Syndrome ,Hematologic Malignancies Lymphoma ,Chronic Lymphocytic ,Refractory Myelofibrosis ,Comparing Ponatinib ,Newly Diagnosed ,Immune Therapeutic Treatment ,Pediatric Patients ,Primary Findings ,Myeloproliferative Neoplasms ,Inhibitor Zilurgisertib ,Single Arm Study ,Refractory Follicular Lymphoma ,Updated Results ,Mantle Cell Non Hodgkin Lymphoma ,Retrospective Observational Cohort Study ,Long Term Follow Up Results ,Chronic Myeloid Leukemia ,Molecular Landmark Response ,Ponatinib Treatment Predicts Outcomes ,Heavily Pretreated Patients ,Chronic Phase Myeloid Leukemia ,Year Data ,Hoc Analysis ,Patient Responses ,Mutation Status ,Year Update ,Dose Optimization Study ,Three Starting Doses ,Clinical Outcomes ,With Polycythemia Vera ,Receiving Ruxolitinib ,Longitudinal Analysis ,Leukemic Transformation ,Lower Risk Myelofibrosis ,Essential Thrombocythemia ,Matched Cohort Analysis ,Molecular Subtyping ,Diffuse Largeb Cell Lymphoma Lines ,Tafasitamab Activity ,Lymphoma Biology Translational ,Year Efficacy ,Final Results ,Aggressive Non Hodgkin Lymphoma ,Medicinal Product ,Millennium Pharmaceuticals ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Looking Statements ,